Curcumin, a natural p300-specific histone acetyltransferase inhibitor, possesses beneficial effects in addition to ACE inhibitor after myocardial infarction in rats

Curcumin, a natural p300-specific histone acetyltransferase inhibitor, possesses beneficial effects in addition to ACE inhibitor after myocardial infarction in rats

Tatsuya Morimoto1, Yoichi Sunagawa1, Hiromichi Wada1, Tomohide Takaya1, Shigeki Yanagi3, Akihiro Sugimoto3, Masaki Tsukashita3, Akira Marui3, Tadashi Ikeda3, Masatoshi Fujita4, Akira Shimatsu1, Toru Kita2, Koji Hasegawa1.

  1. Division of Translational Research, Kyoto Medical Center, National Hospital Organization, Kyoto, Japan.
  2. Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  3. Department of Cardiovascular Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  4. Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

第73回日本循環器学会学術集会 (大阪), 2009/03/21 (ポスター).

Abstract

Background: Recently we found that curcumin, a p300 histone acetyltransferase inhibitor, prevents the deterioration of systolic function in two independent rat models of heart failure. To apply this novel theraphy in the clinical setting, it should be clarified whether curcumin possesses additional effects on conventional therapy by angiotensin converting enzyme inhibitors (ACEI).

Objective: The purpose of this study is to examine the effect of ACEI/curcumin combinatnion therapy on heart failure after myocardial infarction (MI).

Methods: One week after coronary ligation, 32 rats were randomly assigned to treatment with curcumin (50 mg/kg/day), enalapril (ACEI, 10 mg/kg/day), curcumin plus enalapril, or their solvents (control) for 6 weeks.

Results: There were no differences among 4 groups in all data examined before treatment. After treatment, LV fractional shortening (FS) was significantly higher in the ACEI group (29.0%) and in the curcumin group (28.7%) than the vehicle group (21.6%). Notably, LVFS significantly (p < 0.05) increased by ACEI/curcumin combination therapy (34.7%) compared with therapy by either ACEI or curcumin. LV wall thickness and cardiomyocyte diameter were significantly smaller in the ACEI curcumin thatn the ACEI group.

Conclusion: A natural compound, curcumin, had beneficial effects on LV systolic function in addition to ACEI after rat MI. Thus, this non-toxic dietary compound will be applicable for heart failure therapy in the clinical setting.